All treatments
Treatment
Farletuzumab ecteribulin clinical trials
2 indexed studies · 1 currently recruiting
- RecruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
This study is testing a new drug, Farletuzumab Ecteribulin, for certain advanced cancers like ovarian, endometrial, and some breast and lung cancers. Researchers want to see if it's safe, how well it works, and find the best dose.
For: Solid TumorUnited States · France · Japan - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Open-label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies
This study is testing a new medicine called farletuzumab ecteribulin for people with advanced non-small cell lung cancer that has spread and hasn't responded to previous treatments. It aims to understand the side effects and how safe the new drug is.
For: Metastatic Non-Small Cell Lung CancerSpain · France